US2013181174A1PendingUtilityA1

Metal-ligand coordination compounds

53
Assignee: PAN JUNYOUPriority: Sep 23, 2010Filed: Sep 1, 2011Published: Jul 18, 2013
Est. expirySep 23, 2030(~4.2 yrs left)· nominal 20-yr term from priority
C07F 15/0086C07F 15/0033Y02E10/549C09K 11/06C09K 2211/185C09K 2211/1029C09K 2211/1011H10K 85/342H10K 85/361H10K 50/11H10K 2101/10H01L 51/0085
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to novel metal-ligand coordination compounds of the general formula T1-(A-T2)i, where T1 and T2 represent metal-ligand coordination compounds, to the use thereof in a device, and to a formulation and a device which comprise the novel compounds.

Claims

exact text as granted — not AI-modified
1 - 17 . (canceled) 
     
     
         18 . A compound of the following formula (1)
     T -( A - T   2 ) i   formula (1)
   where   T 1  is an i-valent unit of the formula M 1 (L 1 ) n , and   T 2  is on each occurrence, identically or differently, a monovalent unit of the formula M 2 (L 2 ) m ;   A is a divalent unit which contains a conjugation-interrupting unit;   M 1  and M 2  are, independently of one another and identically or differently on each occurrence, selected from the group consisting of the main-group metals, transition metals, lanthanoids and actinoids;   L 1  and L 2  are, independently of one another and identically or differently on each occurrence, mono- or polydentate organic ligands, so that the units of the formulae M 1 (L 1 ) n  and M 2 (L) 2   m  represent metal-ligand coordination compounds;   i is an integer greater than or equal to 1;   n and m are, independently of one another, an integer greater than or equal to 2;   with the proviso that T 1  and T 2  are bonded to A via atoms of the ligands L 1  and L 2 .   
     
     
         19 . The compound according to  claim 18 , wherein the unit L 1 -A-L 2  bridging T 1  and T 2  contains at least 10 non-hydrogen atoms. 
     
     
         20 . The compound according to  claim 18 , wherein M 1  and M 2  are selected, independently of one another and identically or differently on each occurrence, from the group consisting of Ir, Ru, Os, Eu, Pt, Zn, Mo, W, Rh and Pd. 
     
     
         21 . The compound according to  claim 18 , wherein A is a divalent unit selected from the group consisting of the following:
 linear or branched C 1-12 -alkylene,   C 3-8 -cycloalkylene,   linear or branched mono(C 1-12 -alkyl)silylene,   linear or branched di(C 1-12 -alkyl)silylene,   linear or branched tri(C 1-12 -alkyl)silylene,   a silylene group which is substituted by one, two or three mono- or polycyclic aromatic or heteroaromatic ring systems having 5 to 60 aromatic ring atoms,   linear or branched Si1-5-silylene,   linear or branched C1-12-alkyloxy-C1-12-alkylene,   linear or branched aryl-C1-12-alkyloxy-C1-12-alkylene, where aryl is a mono- or polycyclic aromatic or heteroaromatic ring system having 5 to 60 aromatic ring atoms,   linear or branched C1-12-alkylthio-C1-12-alkylene, sulfone,   linear or branched C1-12-alkylene sulfone, sulfone oxide and   linear or branched C 1-12 -alkylene sulfone oxide,   where one or more H atoms of the said groups which represent A is optionally replaced by
 F, Cl, Br, I, 
 a further C 1-12 -alkyl or C 3-8 -cycloalkyl, where one or more CH 2  groups of the alkyl or cycloalkyl is optionally replaced by heteroatoms, or a mono- or polycyclic aromatic or heteroaromatic ring system having 5 to 60 aromatic ring atoms, and 
 where one or more CH 2  groups of the said groups which represent A is optionally replaced by a divalent mono- or polycyclic aromatic or heteroaromatic ring system having 5 to 60 aromatic ring atoms, and 
   with the proviso that the divalent unit A can bond to the ligands L 1  or L 2  via any conceivable atom of the unit.   
     
     
         22 . The compound according to  claim 18 , wherein i is equal to 1, 2, 3 or 4. 
     
     
         23 . The compound according to  claim 18 , wherein n is equal to 2, 3, 4, 5 or 6. 
     
     
         24 . The compound according to  claim 18 , wherein m is equal to 2, 3, 4, 5 or 6. 
     
     
         25 . The compound according to  claim 18 , wherein in each case at least one L 1  and/or at least one L 2  is a bidentate ligand. 
     
     
         26 . The compound according to  claim 18 , wherein T 1  and T 2  are phosphorescent metal-ligand coordination compounds. 
     
     
         27 . The compound according to  claim 18 , wherein an emission band of the unit T 1  is in a wavelength range which overlaps with the wavelength range of an absorption band of the unit T 2 . 
     
     
         28 . The compound according to  claim 18 , wherein T 2  is a dye. 
     
     
         29 . An electronic device comprising the compound according to  claim 18 . 
     
     
         30 . An organic electroluminescent device containing a the compound according to  claim 18 , wherein the device is an organic light-emitting diode, an organic light-emitting electrochemical cell or an organic light-emitting transistor. 
     
     
         31 . The organic electroluminescent device according to  claim 30 , wherein the device has a planar shape and/or is in the form of a fibre. 
     
     
         32 . An electronic device comprising the compound according to  claim 18 , wherein the device is selected from the group consisting of an organic integrated circuit, an organic field-effect transistor, an organic thin-film transistor, an organic solar cell, a dye-sensitised organic solar cell, an organic optical detector, an organic photoreceptor, an organic field-quench device, an organic laser diode and an organic plasmon emitting device. 
     
     
         33 . A formulation comprising at least one compound according to  claim 18  and at least one solvent. 
     
     
         34 . The formulation according to  claim 33 , wherein the formulation is a solution, dispersion or emulsion. 
     
     
         35 . Compound according to  claim 18  or device according to  claim 30  for the therapy, prophylaxis and/or diagnosis of diseases and/or cosmetic conditions.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.